Literature DB >> 27160192

Erratum to: Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Erwann P Loret1, Albert Darque2,3, Elisabeth Jouve4, Elvenn A Loret2, Corinne Nicolino-Brunet2, Sophie Morange5, Elisabeth Castanier5, Josiane Casanova5, Christine Caloustian5, Charléric Bornet3, Julie Coussirou3, Jihen Boussetta3, Vincent Couallier6, Olivier Blin4, Bertrand Dussol5, Isabelle Ravaux2.   

Abstract

Year:  2016        PMID: 27160192      PMCID: PMC4862173          DOI: 10.1186/s12977-016-0264-y

Source DB:  PubMed          Journal:  Retrovirology        ISSN: 1742-4690            Impact factor:   4.602


× No keyword cloud information.

Erratum to: Retrovirology (2016) 13:21 DOI 10.1186/s12977-016-0251-3

The original version of this article unfortunately contained a mistake. The “Acknowledgement” section was incorrect and included Dr. Catherine Tamalet. Dr. Catherine Tamalet should not be included in the “Acknowledgement” section for the following reasons: Dr. Catherine Tamalet requests to be withdrawn from the “Acknowledgements” section in this article, on the following grounds: (a) No permission was asked of her to be acknowledged. (b) She did not read the manuscript before its publication. (c) The method depicted in the “Methods” section to quantify HIV DNA [“Generic HIV assay (Biocentric, Bandol, Provence) with a cut off of 20 copies/million of peripheral blood mononuclear cells (PBMC)”] is not the method employed in her laboratory. Dr. Tamaret routinely employs an “in-House” method with a cut-off of 20 copies. Dr. Thamalet was in the acknowledgement for fruitful discussion and not for her participation to the study. Dr. Catherine Tamalet has been removed from the original article [1].
  1 in total

1.  Intradermal injection of a Tat Oyi-based therapeutic HIV vaccine reduces of 1.5 log copies/mL the HIV RNA rebound median and no HIV DNA rebound following cART interruption in a phase I/II randomized controlled clinical trial.

Authors:  Erwann P Loret; Albert Darque; Elisabeth Jouve; Elvenn A Loret; Corinne Nicolino-Brunet; Sophie Morange; Elisabeth Castanier; Josiane Casanova; Christine Caloustian; Charléric Bornet; Julie Coussirou; Jihen Boussetta; Vincent Couallier; Olivier Blin; Bertrand Dussol; Isabelle Ravaux
Journal:  Retrovirology       Date:  2016-04-01       Impact factor: 4.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.